Results 291 to 300 of about 825,352 (312)

Rewriting the dendritic cell code in cancer-from subset identity to immunotherapeutic design. [PDF]

FEBS Lett
Silva Barcelos EC, Ricciuti D, Mondanelli G, Gargaro M.   +3 more
europepmc   +1 more source

Histone methyltransferase DOT1L differentially affects the development of dendritic cell subsets

Bouma RG, de Leeuw W, Wang AZ, Malik M, Stolwijk JG, Konijn VA, Mensink A, Proost N, Nijen Twilhaar MK, van Welsem T, Seyed Toutounchi N, Affandi AJ, van Dinter JT, van Leeuwen F, den Haan JM.   +14 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions

Ca-A Cancer Journal for Clinicians, 2023
Balazs Dome
exaly  

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023

exaly  

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Boris Böll, Victoria Metaxa   +2 more
exaly  

An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma

Ca-A Cancer Journal for Clinicians, 2022
Elshad Hasanov, Marion Smits, Priscilla K Brastianos   +2 more
exaly  

Current treatment and recent progress in gastric cancer

Ca-A Cancer Journal for Clinicians, 2021
Smita S Joshi, Brian D Badgwell
exaly  

The rapidly changing landscape in mature T‐cell lymphoma (MTCL) biology and management

Ca-A Cancer Journal for Clinicians, 2020
Enrica Marchi
exaly  

Oral cavity and oropharyngeal squamous cell carcinoma—an update

Ca-A Cancer Journal for Clinicians, 2015
Angela C Chi
exaly  

A review of cancer immunotherapy toxicity

Ca-A Cancer Journal for Clinicians, 2020
Lucy Boyce Kennedy
exaly